Protein-tyrosine phosphatase 1B (PTP1B) (PTP1B)

Protein-tyrosine phosphatase 1B (PTP1B) is a non-receptor tyrosine phosphatase that acts as a key negative regulator of insulin and leptin signaling pathways [UniProt, 2024; Nature Reviews Drug Discovery, 2018]. It functions by dephosphorylating the phosphotyrosine residues of the activated insulin receptor and insulin receptor substrates, thereby terminating the signal [NCBI Gene, 2024; FEBS Letters, 2003]. Due to its role in attenuating these metabolic signals, PTP1B is a major therapeutic target for the treatment of type 2 diabetes and obesity [Nature Reviews Drug Discovery, 2018; Diabetology & Metabolic Syndrome, 2012]. Additionally, PTP1B has been implicated in cancer biology, where it can act as either an oncogene or a tumor suppressor depending on the cellular context, notably promoting HER2-positive breast cancer [FEBS Letters, 2003]. Drug development efforts have historically struggled with the highly polar and conserved nature of the PTP1B active site, which complicates the creation of cell-permeable and selective inhibitors [Nature Reviews Drug Discovery, 2018]. A significant challenge is achieving selectivity over the closely related T-cell protein-tyrosine phosphatase (TCPTP), as its inhibition can lead to systemic inflammation and immune issues [UniProt, 2024]. Modern strategies to target PTP1B include the development of allosteric inhibitors and antisense oligonucleotides to improve specificity and pharmacological properties [Nature Reviews Drug Discovery, 2018]. Note: The input name was marked as incorrect because it refers to a protein family or group rather than a single specific target molecule.

Other names

PTPN1Protein-tyrosine phosphatase non-receptor type 1PTP-1B

Inhibition of PTP1B phosphatase activity to enhance and prolong insulin and leptin receptor signaling.